Discuss the latest strategies to harness the immune system for the development of innovative therapeutics.

Featuring 30+ presentations, the event brings together over 120 attendees from leading pharma, biotech and academic organisations designing innovative strategies and technologies for more effective cancer immunotherapy development.

Agenda at a Glance

Day One

Track 1: Discovery & Development: Cell Therapies & Antibody Approaches

• NextGen cell-based immunotherapies: CAR-T, TCR, and TIL  
• Case studies in bispecific antibodies and checkpoint inhibitors 
• Workshop: Improving The Therapeutic Index For Cell Engagers 

Track 2: Biomarkers, Precision Medicine & Spatial Biology in Immuno-Oncology

• Biomarker strategies in the era of PD-1 checkpoint combination therapies​ 
• New technologies: CyTOF, mass spec, multiplexing, immunohistochemistry, serum biomarkers 
• Spatial biology to improve clinical trial outcomes and biomarker discovery 
• Workshop: Harnessing Spatial Technologies For Immunotherapy Research 

Day Two

Track 1: Discovery & Development: Intratumoral Immuno- & Combination Therapies​ & Small Molecules as IO Therapeutics

Part 1 – Intra-tumoral & Combination Therapies  

• Oncolytic and non-oncology viruses and agonists 
• Cancer vaccine development 
• Rationale of different combinations, including combination of IO agents as well as radiotherapy & chemotherapy​ 

Part 2 – Small Molecules as Immuno-Oncology Therapeutics 

• Advances in modulating immuno-metabolism and immuno-suppression with small molecules 
• New approaches for small molecule IO targets  
• Workshop: Small Molecules As IO Targets  

Track 2: Translational & Preclinical and Clinical Development

• Preclinical models, including humanised & 3D mouse models 
• Translational imaging and screening methods 
• Safety & Toxicity considerations 
• Approaches to clinical trial design & development